Trial Profile
A study evaluating efficacy of anti-EGFR-based conversion chemotherapy in RAS wildtype colorectal cancer patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2017
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology